Historique
Article de Périodique
International cannabis policies and their association with cannabis use, cannabis use disorder, and other psychiatric disorders (2026)
Auteur(s) :
FREEMAN, T. P. ;
THORNE, R. L. ;
WADSWORTH, E. ;
CARNEY, T. ;
CASTILLO-CARNIGLIA, A. ;
CERDA, M. ;
KALAYASIRI, R. ;
KILMER, B. ;
LORENZETTI, V. ;
MANTHEY, J. ;
MYRAN, D. T. ;
RIVERA-AGUIRRE, A. ;
RYCHERT, M. ;
WILSON, J. ;
YIMER, T. ;
HALL, W.
Année
2026
Page(s) :
615-626
Langue(s) :
Anglais
Refs biblio. :
105
Domaine :
Drogues illicites
Discipline :
PSY (Psychopathologie / Psychopathology)
Thésaurus géographique
INTERNATIONAL
;
CANADA
;
ETATS-UNIS
;
URUGUAY
;
EUROPE
;
AFRIQUE
;
OCEANIE
;
ASIE
Thésaurus mots-clés
CANNABIS
;
POLITIQUE
;
PSYCHOPATHOLOGIE
;
EVOLUTION
;
LEGALISATION
;
PREVALENCE
;
PSYCHOSE
;
HOSPITALISATION
;
DECRIMINALISATION
;
USAGE THERAPEUTIQUE
;
USAGE RECREATIF
Note générale :
Comment: Hasin D. (2026) Cannabis use, regulation, and mental illness. The Lancet Psychiatry, Vol. 13, n° 7, p. 538-539. https://doi.org/10.1016/S2215-0366(26)00170-7
Résumé :
Cannabis policies vary from strict prohibition to commercialised legalisation and are rapidly evolving worldwide. Here, we reviewed evidence for associations between international cannabis policy changes from 2000-25 and cannabis use, cannabis use disorder, and other psychiatric disorders. Commercialised legal markets for non-medical use in Canada and the USA were associated with increased prevalence of cannabis use and cannabis use disorder in adults and increases in cannabis potency since legalisation. There was no consistent evidence for associations between policy change and the prevalence or incidence of psychotic disorders. Commercialised legalisation was associated with an increase in hospital admissions for psychosis, and for psychotic disorders comorbid with cannabis use disorder. Poorly regulated legal access to medical cannabis, in the absence of efficacy and safety data, could increase risk of harm. Policies that limit commercialisation, such as strictly regulated legalisation of medical or non-medical supply, were not as strongly associated with cannabis use or psychiatric disorders, but long-term evaluation is needed. There was little evidence that decriminalisation of non-medical cannabis in Europe, Africa, Oceania, and Asia was associated with cannabis use or psychiatric disorders. [Author's abstract]
Affiliation :
Addiction and Mental Health Group, Department of Psychology, University of Bath, Bath, UK